

9th December 2021

Proteins for Life

Virtual Growth Days Webinar
Bent U. Frandsen, CEO
















EXPRES²ION
BIOTECHNOLOGIES

Forward-looking statements and disclaimer

This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. ExpreS²ion Biotech does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Deep Pipeline for Value Creation

Development Progress

DISEASE	Project/Target	Discovery	Pre-clinical Pharmacology	cGMP / Tox	Phase 1	Phase 2	Phase 3	Market Potential	Partner/Funding
Coronavirus 	ABNCoV2/SARS-CoV-2 cVLP					I/IIa BN: II		> 30 billion EUR	adaptVAC   PREVENT-nCoV
Breast Cancer 	ES2B-C001/HER2 cVLP							> 10 billion EUR	100% ExpreS ² ion
Influenza 	Hemagglutinin							> 4 billion EUR	 INDIGO
Malaria: 								> 0.4 billion EUR	
1: Blood-Stage	RH5					I/IIa			 MultiViVax
2: Blood-Stage	RH5-VLP								 
3: Transmission	Pfs 48/45								 OptimalVax 
4: Placenta-Borne	VAR2CSA			Ia / Ib					 
5: Blood-Stage	CYRPA complex								 DISCOVERIES FOR HUMANITY

AdaptVac is a joint venture between ExpreS²ion (34% owned) and NextGen Vaccines (66% owned)




ABNCoV2 COVID-19 Vaccine Update

Bavarian Nordic-sponsored Phase II clinical trial demonstrates strong boost across variants


- ABNCoV2 induces strong booster effect**
 - Booster vaccination with ABNCoV2 increased the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodies
- ABNCoV2 boosts responses to all variants tested**
 - High percentage of subjects with strong boost responses especially individuals with low starting titers
- ABNCoV2 induced strong boost response to the Delta variant**
 - Similar fold-increases against the Delta variant following ABNCoV2 booster
- Scale-up Manufacturing**
 - The vaccine bulk manufacturing for the Phase 3 trial is on-going at a contract manufacturer
 - Filling planned at Bavarian Nordic's own facility
 - Commercial manufacturing scale-up planned for H1 2022

Phase II clinical trial on-going: Positive topline results in 1st of 3 study arms



Data released 5 December 2021




Next steps: Phase II final read-out Q1 2022 / Phase III initiation H1 2022, initial readout H2 2022, launch H1 2023






COVID-19 Value to ExpreS²ion

Institutional analysts have higher sales and approval assumptions




Financials – Fit for Pipeline Progression


Revenues, SEK '000s



Operating costs, SEK '000s



Cash balance, SEK million



A person is shown from the side, holding a piece of paper and drawing several virus-like particles with a blue marker. The particles are spherical with a textured surface and small protrusions. The background is a wooden desk.

Thank you!

Contact:
info@expres2ionbio.com

Proteins
for Life

EXPRES²ION
BIOTECHNOLOGIES